These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3791248)

  • 21. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
    Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?
    Wu ZY; Smithers BM; Anderson C; Roberts MS
    Melanoma Res; 2000 Feb; 10(1):47-54. PubMed ID: 10711640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon-gamma, and/or melphalan.
    Merryman P; Tannenbaum SH; Gralnick HR; Yu K; Arnold WS; Alexander HR; Fraker D; Horne MK
    Thromb Haemost; 1997 Jan; 77(1):53-6. PubMed ID: 9031449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities.
    Briele HA; Djuric M; Jung DT; Mortell T; Patel MK; Das Gupta TK
    Cancer Res; 1985 Apr; 45(4):1885-9. PubMed ID: 3978649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Regional cytostatic perfusion of the extremities in patients with malignant melanoma and soft tissue sarcoma--therapeutic applications and results].
    Eichfeld U; Gläser A; Schneider G; Kraus J; Pauer HJ; Schwarz I
    Zentralbl Chir; 1993; 118(2):63-8. PubMed ID: 7682024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
    Thompson JF; Lai DT; Ingvar C; Kam PC
    Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
    Vrouenraets BC; in't Veld GJ; Nieweg OE; van Slooten GW; van Dongen JA; Kroon BB
    Eur J Surg Oncol; 1999 Oct; 25(5):503-8. PubMed ID: 10529261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possibilities of improving the parameters of hyperthermia in regional isolated limb perfusion using epidural bupivacaine and accurate temperature measurement of the three layers of limb tissue.
    Jastrzebski T; Sommer A; Swierblewski M; Lass P; Rogowski J; Drucis K; Kopacz A
    Melanoma Res; 2006 Jun; 16(3):249-57. PubMed ID: 16718272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Continuous determination of the blood density during haemodialysis (author's transl)].
    Holzer H; Pogglitsch H; Hinghofer-Szalkay H; Kenner T; Leopold H; Passath A
    Wien Klin Wochenschr; 1979 Nov; 91(22):762-5. PubMed ID: 516747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leakage measurement during selective limb perfusion using a gamma probe.
    Sandrock D; Horst F; Gatzemeier W; Ghorbani M; Rauschecker H; Munz DL; Emrich D
    Eur J Nucl Med; 1996 May; 23(5):534-8. PubMed ID: 8698058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The complications of isolated limb perfusion.
    Rosin RD
    Surg Technol Int; 1997; 6():143-50. PubMed ID: 16160967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.